- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…Endpoints · 1mo ago↗ source
- A new Westlake-backed biotech takes aim at migrainesVedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.BioPharma Dive · 1mo ago↗ source
- Opinion: As a physician, I have never been more concerned about rates of congenital syphilis“As a physician and former public health official, I have never been more concerned about those rates of congenital syphilis,” writes Jeffrey D. Klausner.